Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $98,700.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $16.45, for a total transaction of $98,700.00. Following the transaction, the general counsel now directly owns 105,386 shares of the company’s stock, valued at $1,733,599.70. This represents a 5.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $15.75 on Friday. The stock has a 50-day moving average of $16.47 and a 200 day moving average of $16.38. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -10.29 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Institutional Trading of Centessa Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Atria Investments Inc grew its position in Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after purchasing an additional 1,116 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Centessa Pharmaceuticals by 88.1% in the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock worth $4,237,000 after acquiring an additional 124,075 shares during the period. FMR LLC grew its holdings in shares of Centessa Pharmaceuticals by 4.6% in the third quarter. FMR LLC now owns 2,916,494 shares of the company’s stock worth $46,635,000 after acquiring an additional 129,300 shares during the period. Ally Bridge Group NY LLC bought a new stake in shares of Centessa Pharmaceuticals in the third quarter worth $4,951,000. Finally, Suvretta Capital Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the third quarter worth $1,119,000. 82.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Finally, Morgan Stanley restated an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.